Clinical trials: Psoriasis Vulgaris
Psoriasis Vulgaris
An Exploratory Trial Investigating the Neurogenic Component in Psoriasis Vulgaris by Use of Botulinum Toxin A
The purpose of this study is to evaluate the anti-psoriatic effect of injected Botulinum toxin type A compared to that of injected vehicle.
- Trial name
- NCT02577185
- Testing
- Botulinum Toxin Type A, Sodium chloride 9 mg/ml
- Where
- 2 sites in Denmark
- Volunteers
- 10 people
- Sponsor
- LEO Pharma
Psoriasis of Scalp, Psoriasis Vulgaris
Apremilast Treatment for Pruritus and Quality of Life in Scalp Psoriasis
A phase 4 multicenter, randomized, placebo-controlled Study evaluating the Effect of Apremilast on Pruritus and Quality of Life of Patients with moderate-to-severe Scalp Psoriasis
- Trial name
- APRESCALP (NCT03553433)
- Testing
- Apremilast 30mg
- Where
- 4 sites in Switzerland
- Volunteers
- 90 people
- Sponsor
- University of Zurich
Psoriasis Vulgaris
Narrowband UVB Light Therapy to Patients With Dark Skin Types Who Have 10% of Their Body Involved With Psoriasis Vulgaris.
This study offers narrowband UVB light therapy to patients with both light and dark skin types who have 10% of their body involved with psoriasis vulgaris.
- Trial name
- NCT00220025
- Testing
- Phototherapy
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Mary Sullivan-Whalen
Psoriasis Vulgaris
An Exploratory Psoriasis Plaque Test Study With Different Dose Combinations of Calcipotriol Plus Betamethasone Dipropionate in the Daivobet® Gel Vehicle in Psoriasis Vulgaris
The purpose of this study is to evaluate the antipsoriatic effect of 5 different combinations of calcipotriol plus betamethasone dipropionate in Daivobet® gel vehicle in compared to Daivobet® gel in order to explore/find other…
- Trial name
- NCT01837576
- Testing
- Calcipotriol plus BDP gel in different doses
- Where
- France
- Volunteers
- 24 people
- Sponsor
- LEO Pharma
Psoriasis
LEO 90105 Ointment in Japanese Subjects With Psoriasis
The purpose of this study is to compare the efficacy of LEO 90105 ointment applied once daily with Dovonex® ointment applied twice daily and with Rinderon®-DP ointment applied once daily in Japanese subjects with psoriasis…
- Trial name
- NCT01422434
- Testing
- LEO 90105 = calcipotriol + betamethasone dipropionate, Dovonex® = calcipotriol, Rinderon® - DP = betamethasone dipropionate
- Where
- Japan
- Volunteers
- 676 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris, Inflammation
The Efficacy of Topical Formulation Containing Ciplukan (Physalis Angulata Linn.) on Psoriasis Vulgaris Lesions
Psoriasis vulgaris is a chronic inflammatory skin disease mediated by the immune system, with a complex pathogenesis that requires long-term therapy.
- Trial name
- NCT06887322
- Testing
- Ciplukan, Bethametasone valerate 0,1% cream
- Where
- Indonesia
- Volunteers
- 40 people
- Sponsor
- Universitas Padjadjaran
Atopic Dermatitis, Atopic Dermatitis Eczema
Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1%
The investigational lotion is envisaged as an short- and long term "Ease \& Prevent" monotherapy for adults and children with mild to moderate eczema.
- Conditions
- Atopic Dermatitis, Atopic Dermatitis Eczema, Atopic Rash, Rash
- Trial name
- ATOFEX-1 (NCT05461456)
- Testing
- Fexofenadine Hydrochloride Topical Lotion 1% (OP2101)
- Where
- Bangladesh
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- OrchestratePharma GmbH
Psoriasis Vulgaris, Atopic Dermatitis
The Role Of Neutrophil Proteases As Global Regulators Of Il-1 Family Cytokine Activity In Skin Disorders
Pro-inflammatory cytokines are critically important drivers of inflammatory and autoimmune diseases and cytokine-targeted biologics have been transformative in the treatment of several inflammatory and autoimmune diseases.
- Conditions
- Psoriasis Vulgaris, Atopic Dermatitis, Ichthyosis Vulgaris
- Trial name
- NEUTROPRO (NCT04750161)
- Testing
- No intervention
- Where
- Ireland
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- St. James's Hospital, Ireland
Psoriasis Vulgaris, Diabetes Type 2
Effect of Semaglutide on the Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus
The use of semaglutide in patients with DMT2 and psoriasis contributes to improving the clinical picture of psoriasis and reducing the inflammatory response
- Trial name
- NCT06475586
- Testing
- Semaglutide
- Where
- Bosnia and Herzegovina
- Volunteers
- 30 people
- Sponsor
- University of Banja Luka
Psoriasis Vulgaris, Psoriasis
Tofacitinib Ointment For Chronic Plaque Psoriasis
The study is beng done to test if tofacitinib ointment is safe and effective for people with plaque psoriasis. Two dose strengths of tofacitinib ointment (20 mg/g and 10 mg/g) applied once or twice daily are being tested.
- Trial name
- NCT01831466
- Testing
- tofacitinib ointment 20 mg/g, tofacitinib ointment 10 mg/g
- Where
- 54 sites in United States, Canada and 2 more
- Volunteers
- 476 people
- Sponsor
- Pfizer
Psoriasis Vulgaris
Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients (BIOLOPTIM-BRO)
Biologics, such as brodalumab, are currently the most effective treatment option for patients with moderate-to-severe psoriasis.
- Trial name
- BIOLOPTIM-BRO (NCT04080635)
- Testing
- Venapuncture, Patient questionnaires
- Where
- 7 sites in Belgium
- Volunteers
- 100 people
- Sponsor
- University Hospital, Ghent
Plaque Psoriasis, Psoriasis Vulgaris
Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab
The trial investigates the efficacy and safety of brodalumab against guselkumab in treatment for patients with moderate-to-severe plaque psoriasis who still have some remaining symptoms after ustekinumab treatment.
- Conditions
- Plaque Psoriasis, Psoriasis Vulgaris, Psoriasis
- Trial name
- COBRA (NCT04533737)
- Testing
- Brodalumab, Guselkumab
- Where
- 65 sites in Austria, Belgium and 10 more
- Volunteers
- 113 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
Topical Double-blind, Randomized, Placebo-controlled Study in Psoriasis Patients
In this study, the safety, tolerability and efficacy of DLX105 administered topically onto the psoriatic lesion of mild-to-moderate psoriasis patients will be investigated.
- Trial name
- NCT01936337
- Testing
- DLX105 Hydrogel
- Where
- 3 sites in Austria, Germany
- Volunteers
- 59 people
- Sponsor
- Delenex Therapeutics AG
Psoriasis, Psoriasis Vulgaris
Iontophoresis in Psoriasis
Iontophoresis potentially may be a good alternative to improved delivery of corticosteroids. Study Investigators propose to use iontophoresis to increase dexamethasone delivery into thick psoriasis plaques.
- Conditions
- Psoriasis, Psoriasis Vulgaris, Skin Diseases
- Trial name
- NCT03979664
- Testing
- Activapatch intellidose 2.5 using active Iontophoresis, Activapatch intellidose 2.5 using inactive Iontophoresis, Dexamethasone
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Psoriasis Vulgaris
A Short-contact Plaque Test Study With Daivobet® Gel in Psoriasis Vulgaris
The purpose of this study is to evaluate the anti-psoriatic effect of Daivobet® gel applied then removed after 10 minutes (+/- 2 minutes), Daivobet® gel applied then removed after 20 minutes (+/- 2 minutes) compared with…
- Trial name
- NCT01607853
- Testing
- Daivobet® gel applied then removed after 10 minutes (+/- 2 minutes), Daivobet® gel applied then removed after 20 minutes (+/- 2 minutes), Daivobet® gel applied for 24 hours (+/- 2 hours)
- Where
- France
- Volunteers
- 24 people
- Sponsor
- LEO Pharma
Plaque Psoriasis
Real-life Evaluation of the Daivobet® Gel Applicator
This study aims to describe the patient population being treated and evaluate their treatment adherence and treatment outcomes during treatment of scalp psoriasis with Daivobet® gel Applicator for 4 weeks.
- Trial name
- ASAP PSO (NCT02856542)
- Testing
- calcipotriol/betamethasone dipropionate gel in Applicator
- Where
- France
- Volunteers
- 1,560 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris, Plaque Psoriasis
A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis
The aim of this study is to evaluate safety, tolerability, and efficacy of PRCL-02 in moderate to severe chronic plaque psoriasis
- Trial name
- NCT03614078
- Testing
- PRCL-02
- Where
- 16 sites in Canada, Slovakia and 1 more
- Volunteers
- 92 people
- Sponsor
- PRCL Research Inc.
Psoriasis, Metabolic Syndrome
Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome
This study was a randomized, open-label, parallel-group, active comparator controlled study with two treatment arms designed to answer the question whether the combination of Secukinumab with lifestyle intervention could…
- Trial name
- METABOLYX (NCT03440736)
- Testing
- Secukinumab, Life-style intervention
- Where
- 75 sites in Germany
- Volunteers
- 781 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis Vulgaris
LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis
To compare the efficacy and safety of LEO 80185 gel with Dovobet® ointment in the treatment of psoriasis in Japanese subjects.
- Trial name
- NCT02668692
- Testing
- LEO 80185 gel, Dovobet ® ointment
- Where
- Japan
- Volunteers
- 213 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
Dermatologic Research Evaluation and Monitoring of Sleep in Moderate-to-Severe Psoriasis
Getting enough sleep is important for maximizing health and well-being. When it comes to health, sleep is as vital as regular exercise and eating a balanced diet.
- Trial name
- DREAMS-PSO (NCT05102474)
- Testing
- Polysomnography (PSG)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco